Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: An adjusted comparison of mortality and morbidity

American Journal of Hematology

Volumn 89, Issue 1, 2014, Pages 41-46

  Moulis, Guillaume ^a,b,c   Sailler, Laurent ^a,b,c   Sommet, Agnès ^a,b,c   Lapeyre Mestre, Maryse ^a,b,c   Derumeaux, Hélène ^a,b   Adoue, Daniel ^a,b  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

ADULT; ADVERSE OUTCOME; ARTICLE; BRAIN ISCHEMIA; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE EFFECTIVENESS; DRUG FATALITY; DRUG INDUCED CANCER; EVENTRATION; FEMALE; FOLLOW UP; HUMAN; INFECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MUCOSAL BLEEDING; OUTCOME ASSESSMENT; PERITONITIS; PORTAL VEIN THROMBOSIS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIMARY IMMUNE THROMBOCYTOPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPLENECTOMY; SURGICAL MORTALITY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MORBIDITY; MORTALITY; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RISK FACTORS; SPLENECTOMY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892872044     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23580     Document Type: Article

References (36)

1. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190-4207.
2. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-186.
3. Haute Autorité de Santé. Purpura thrombopénique immunologique de l'enfant et de l'adulte. Protocole national de diagnostic et de soins 2009.Available at: http://www.has-sante.fr/portail/upload/docs/application/pdf/200912/ald_2_pnds_pti_imune_enft_adulte_web.pdf. Accessed on 31 March 2013.
4. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: A systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004;104:2623-2634.
5. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000;160:1630-1638.
6. Vianelli N, Galli M, de Vivo A, et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: Long-term results of 402 cases. Haematologica 2005;90:72-77.
7. Schwartz J, Leber MD, Gillis S, et al. Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol 2003;72:94-98.
8. Mikhael J, Northridge K, Lindquist K, et al. Short-term and long-term failure of laparoscopic splenectomy in adult immune thrombocytopenic purpura patients: A systematic review. Am J Hematol 2009;84:743-748.
9. Vianelli N, Palandri F, Polverelli N, et al. Splenectomy as a curative treatment for immune thrombocytopenia: A retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica 2013;98:875-880.
10. Thomsen RW, Schoonen WM, Farkas DK, et al. Risk for hospital contact with infection in patients with splenectomy: A population-based cohort study. Ann Intern Med 2009;151:546-555.
11. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001;98:952-957.
12. Arnold DM, Heddle NM, Carruthers J, et al. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood 2012;119:1356-1362.
13. Auger S, Duny Y, Rossi JF, Quittet P. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: A meta-analysis. Br J Haematol 2012;158:386-398.
14. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: Results of a prospective multicenter phase 2 study. Blood 2008;112:999-1004.
15. Medeot M, Zaja F, Vianelli N, et al. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: Long-term follow-up results. Eur J Haematol 2008;81:165-169.
16. Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012;119:5989-5995.
17. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007;146:25-33.
18. Khellaf M, Michel M, Fain O, et al. Analyse épidémiologique de 250 patients atteints de purpura thrombopénique immunologique ayant reçu du rituximab. Premiers résultats du registre national prospectif observationnel «PTI-Ritux». Rev Med Int 2012;33:A57-A58.
19. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood 2009;113:2386-2393.
20. Kurth T, Walker AM, Glynn RJ, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006;163:262-270.
21. Martens EP, de Boer A, Pestman WR, et al. Comparing treatment effects after adjustment with multivariable Cox proportional hazards regression and propensity score methods. Pharmacoepidemiol Drug Safe 2008;17:1-8.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-383.
23. Yong M, Thomsen RW, Schoonen WM, et al. Mortality risk in splenectomised patients: A Danish population-based cohort study. Eur J Int Med 2010;21:12-16.
24. Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: The choice between splenectomy or a medical therapy as a second-line treatment. Blood 2012;120:960-969.
25. Moulis G, Sailler L, Sommet A, et al. Prevalence of pneumococcal vaccination in adult immune thrombocytopenia patients exposed to rituximab or to splenectomy. Eur J Haematol 2013;90:438-439.
26. Marassi A, Vignali A, Zuliani W, et al. Splenectomy for idiopathic thrombocytopenic purpura: Comparison of laparoscopic and conventional surgery. Surg Endosc 1999;13:17-20.
27. Shimomatsuya T, Horiuchi T. Laparoscopic splenectomy for treatment of patients with idiopathic thrombocytopenic purpura. Comparison with open splenectomy. Surg Endosc 1999;13:563-566.
28. Ruiz-Tovar J, Alonso Hernández N, Pérez de Oteyza J, et al. Laparoscopic vs open splenectomy in the treatment of idiopathic thrombocytopenic purpura. Cir Esp 2007;81:192-196.
29. Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood 2013;121:4782-4790.
30. Vecchio R, Cacciola E, Cacciola RR, et al. Portal vein thrombosis after laparoscopic and open splenectomy. J Laparoendosc Adv Surg Tech A 2011;21:71-75.
31. Severinsen MT, Engebjerg MC, Farkas DK, et al. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: A Danish population-based cohort study. Br J Haematol 2011;152:360-362.
32. Nørgaard M, Severinsen MT, Lund Maegbaek M, et al. Risk of arterial thrombosis in patients with primary chronic immune thrombocytopenia: A Danish population-based cohort study. Br J Haematol 2012;159:109-111.
33. Enger C, Bennett D, Forssen U, et al. Comorbidities in patients with persistent or chronic immune thrombocytopenia. Int J Hematol 2010;92:289-295.
34. Nørgaard M, Jensen AØ, Engebjerg MC, et al. Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: A Danish population-based cohort study. Blood 2011;117:3514-3520.
35. Michel M, Rauzy OB, Thoraval FR, et al. Characteristics and outcome of immune thrombocytopenia in elderly: Results from a single center case-controlled study. Am J Hematol 2011;86:980-984.
36. Gonzalez-Porras JR, Escalante F, Pardal E, et al. Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia. Eur J Haematol 2013;91:236-241.